<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-14-02756</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0100206</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Hematologic cancers and related disorders</subject><subj-group><subject>Myelodysplastic syndromes</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Prognostic Value of <italic>Isocitrate Dehydrogenase</italic> Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">An <italic>IDH</italic> Meta-Analysis in MDS</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jin</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hu</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yu</surname><given-names>Mengxia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Feifei</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ye</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yin</surname><given-names>Xiufeng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zhuang</surname><given-names>Zhengping</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tong</surname><given-names>Hongyan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Hematology, the First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Institute of Hematology, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Zuo</surname><given-names>Zhuang</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>UT MD Anderson Cancer Center, United States of America</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">zjuhongyantong@163.com</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: JJ HT ZZ. Performed the experiments: CH MY LY. Analyzed the data: CH FC XY. Contributed reagents/materials/analysis tools: CH. Wrote the paper: CH HT.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>17</day><month>6</month><year>2014</year></pub-date>
<volume>9</volume>
<issue>6</issue>
<elocation-id>e100206</elocation-id>
<history>
<date date-type="received"><day>19</day><month>1</month><year>2014</year></date>
<date date-type="accepted"><day>21</day><month>5</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Jin et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Background</title>
<p>Recent genomic sequencing efforts have identified a number of recurrent mutations in myelodysplastic syndromes (MDS) that may contribute to disease progression and overall survival, including mutations in <italic>isocitrate dehydrogenases 1</italic> and <italic>2</italic> (<italic>IDH1</italic> and <italic>IDH2</italic>).</p>
</sec><sec>
<title>Methods</title>
<p>Pretreatment bone marrow (BM) samples were acquired from mononuclear cells in 146 adult patients with de novo MDS from January 2006 to June 2013. Polymerase chain reaction (PCR) and direct sequencing were performed on exon 4 of <italic>IDH1/2</italic> genes and mutation status was correlated with overall survival (OS) and leukemia-free survival (LFS). We then performed a meta-analysis combining previously published and current studies to explore the effect of <italic>IDH</italic> mutations on OS and LFS in MDS.</p>
</sec><sec>
<title>Results</title>
<p>In our study, somatic mutations of either <italic>IDH</italic> gene were discovered in 11 MDS patients (7.53%) and were significantly correlated with poorer OS (<italic>P</italic> = 0.007). <italic>IDH</italic> mutations were specifically associated with a poorer OS in the intermediate-1 risk group by the International Prognostic Scoring System (IPSS) (<italic>P</italic> = 0.039). In addition, we discovered decitabine achieved a better therapeutic effect compared to other treatments in <italic>IDH</italic> mutation-positive patients (<italic>P</italic> = 0.023). We identified six previous studies of <italic>IDH</italic> mutations in MDS. A meta-analysis of these studies included 111 MDS patients <italic>IDH</italic> mutations and 1671 MDS patients with wild-type <italic>IDH1/2</italic>. The hazard ratios (HRs) of OS and LFS for patients with <italic>IDH</italic> mutations were 1.62 (95% CI, 1.27–2.09) and 2.21 (95% CI, 1.48–3.30), respectively.</p>
</sec><sec>
<title>Conclusion</title>
<p>The results from our study and the meta-analysis provide firm evidence that <italic>IDH</italic> mutations are significantly associated with poorer clinical outcomes in MDS. Identification of <italic>IDH</italic> mutations may be pivotal for better risk stratification in MDS patients and improving IPSS score. Additionally, hypomethylating agents may be an effective treatment option for MDS patients with <italic>IDH</italic> mutations.</p>
</sec></abstract>
<funding-group><funding-statement>This study was supported by grants from Zhejiang Province Fund for Distinguished Young Scholars (LR12H08001), the Foundation of Key Innovation Team of Zhejiang Province (2011R50015), National Public Health Grand Research Foundation (201202017), major program of Science Technology Department of Zhejiang Province fund (2013c03043-2) and the National Natural Science Foundation of China (No.30870914, No.81270582). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Myelodysplastic syndromes (MDS) comprise a heterogeneous group of hematological disorders defined by blood cytopenias due to ineffective hematopoiesis and an increased risk of developing acute myeloid leukemia (AML) <xref ref-type="bibr" rid="pone.0100206-Corey1">[1]</xref>, <xref ref-type="bibr" rid="pone.0100206-Nimer1">[2]</xref>. Despite recent advances in therapeutic methods, treatments for MDS are currently tailored to individual patient needs, making the precise forecast of the prognosis an important component of treating patients <xref ref-type="bibr" rid="pone.0100206-Bejar1">[3]</xref>. Current prognostic scoring systems for patients with MDS are mainly based on karyotypic abnormalities and certain clinical features that are used to stratify risk. Although existing systems such as the IPSS <xref ref-type="bibr" rid="pone.0100206-Greenberg1">[4]</xref>, Revised-IPSS <xref ref-type="bibr" rid="pone.0100206-Greenberg2">[5]</xref> and WHO-classification-based Prognostic Scoring System (WPSS) <xref ref-type="bibr" rid="pone.0100206-Malcovati1">[6]</xref> help to estimate patient outcomes and guide treatment decisions, there remains significant variability in prognosis. Hence, novel molecular markers may offer more precise cancer phenotypes and more accurate estimation of prognosis for MDS patients.</p>
<p>Until now, the pathogenesis of MDS has not been clearly identified, but it is generally acknowledged that genetic mutations and dysfunction of gene contribute to the development and progression of this preleukemic disease <xref ref-type="bibr" rid="pone.0100206-Bejar2">[7]</xref>, <xref ref-type="bibr" rid="pone.0100206-Shih1">[8]</xref>. Genetic mutations are not currently used in estimating prognosis in MDS but are likely key determinants of overall survival and clinical phenotypes <xref ref-type="bibr" rid="pone.0100206-GarciaManero1">[9]</xref>. Therefore, contributing gene mutations may supplement current prognostic systems to improve the prediction of prognosis for MDS patients.</p>
<p>IDH 1/2 are key metabolic enzymes that convert isocitrate to α-ketoglutarate (α-KG or 2-oxoglutarate, 2-OG), which is an essential cofactor for α-KG dependent dioxygenases <xref ref-type="bibr" rid="pone.0100206-Reitman1">[10]</xref>, <xref ref-type="bibr" rid="pone.0100206-Chung1">[11]</xref>. These enzymes are associated with diverse cellular processes such as adapting to histone deacetylation, hypoxia, and DNA demethylation <xref ref-type="bibr" rid="pone.0100206-Kaelin1">[12]</xref>. Therefore, <italic>IDH</italic> mutations may be causally linked to the clinical impacts of patients with MDS. We identified 146 patients with primary MDS and analysed <italic>IDH</italic> mutation status with OS and LFS. We then performed a meta-analysis combining our data with those of the published literature to furnish a more accurate estimation of the relationship between <italic>IDH</italic> mutations and MDS.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Patients</title>
<p>One hundred and forty-six adult patients with de novo MDS diagnosed according to World Health Organization (WHO) 2001 criteria <xref ref-type="bibr" rid="pone.0100206-Vardiman1">[13]</xref> were recruited at the department of hematology, the First Affiliated Hospital of Zhejiang University. MDS patients were stratified by cytogenetic risk according to IPSS protocols <xref ref-type="bibr" rid="pone.0100206-Greenberg1">[4]</xref>. All of the subjects were well-informed about the study and provided written informed consent to participate this study. This study was approved by the Institutional Review boards of the First Affiliated Hospital of Zhejiang University. Follow-up data were obtained by telephoning and reviewing patients’ medical records. 7 of 146 patients (4.79%) were lost to follow-up. Treatments were performed for patients including chemotherapy regimens (the GAA regimen (granulocyte-colony stimulating factor (G-CSF) 200 µg/m<sup>2</sup> per day on days 1–14, aclacinomycin 10 mg per day on days 1–14; cytarabine 10 mg/m<sup>2</sup>, days 1–14; n = 2); the GHA regimen (G-CSF 200 µg/m<sup>2</sup> per day on days 1–14, homoharringtonine 1 mg/m<sup>2</sup> per day on days 1–14, cytarabine 10 mg/m<sup>2</sup> per day on days 1–14; n = 6); the DA or IA regimen (daunorubicin 40–45 mg/m<sup>2</sup> per day on days 1–3 or idarubicin 8–12 mg/m<sup>2</sup> per day on days 1–3, cytarabine 100 mg/m<sup>2</sup> per day on days 1–7; n = 8); decitabine (20 mg/m<sup>2</sup>/day, days 1–5 or 15 mg/m<sup>2</sup>, q8 h, days 1–3; n = 44)) and supportive care (antibiotics, androgen, all-<italic>trans</italic> retinoic acid, blood product transfusion and iron chelation therapy; n = 86).</p>
</sec><sec id="s2b">
<title>Mutational Analyses for the IDH1 and IDH2 Genes</title>
<p>Pretreatment BM specimens were enriched for mononuclear cells using Ficoll density gradient centrifugation. Genomic DNA was extracted from cryopreserved mononuclear cells using the DNA Kit (Sangon, Shanghai, China) according to the manufacturer’s instructions. Approximately 100 ng of DNA was used for each PCR reaction. The primer pairs were the same as those designed by Patnaik et al <xref ref-type="bibr" rid="pone.0100206-Patnaik1">[14]</xref>. The PCR amplification conditions were as follows: 95°C for 5 minutes; followed by 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds; and finally, 72°C for 5 minutes. PCR products were directly sequenced on both strands using an ABI 3730 automatic sequencer by Sangon.</p>
</sec><sec id="s2c">
<title>Statistical Analysis</title>
<p>OS end-points were defined as the time from diagnosis of MDS to death due to any cause or to the time of last follow-up. LFS end-points were defined as the time from MDS diagnosis to either AML progression or death or failure or alive without disease progression at the date of most recent follow-up. Length of survival comparisons were analyzed using the Kaplan-Meier method. For categorical parameters, overall group differences were compared with the χ<sup>2</sup> or Fisher exact test. For continuous variables, overall group differences were evaluated with the Mann-Whitney <italic>U</italic> test. A Cox proportional hazards model was performed to evaluate the effect of endpoint on OS and LFS for multivariate analysis. Statistical analysis was performed with SPSS 16.0 software package (SPSS, Chicago, USA). All tests were 2-tailed, and a <italic>P</italic>-value of less than 0.05 was considered statistically significant.</p>
</sec><sec id="s2d">
<title>Meta-analysis of <italic>IDH1/2</italic> Mutations in MDS</title>
<p>To further assess the relationship between <italic>IDH1/2</italic> mutations and MDS risk, we conducted a meta-analysis combining our study data with published studies on <italic>IDH</italic> mutations in MDS <xref ref-type="bibr" rid="pone.0100206-Bejar1">[3]</xref>, <xref ref-type="bibr" rid="pone.0100206-Patnaik1">[14]</xref>, <xref ref-type="bibr" rid="pone.0100206-Thol1">[15]</xref>, <xref ref-type="bibr" rid="pone.0100206-Lin1">[16]</xref>, <xref ref-type="bibr" rid="pone.0100206-Lin2">[17]</xref>, <xref ref-type="bibr" rid="pone.0100206-Lin3">[18]</xref>. Two independent reviewers (CH and MXY) performed a systematic literature search using ISI Web of Science, PubMed and the Cochrane Library for relevant papers published before December 2013 by the search term “(MDS OR myelodysplastic syndrome OR preleukemia OR myelodysplasia) AND (<italic>IDH1</italic> OR <italic>IDH2</italic>).” Reviews and references of related articles were checked for missing information. Eligible papers met all the following criteria: (1) assessed the association between <italic>IDH1/2</italic> mutations and outcomes in MDS; (2) detailed survival information of patients with <italic>IDH1</italic> or <italic>IDH2</italic> mutations; (3) reported the study in English. Animal studies, letters to the editor without original data, reviews and case reports were excluded. In the event of multiple publications from overlapping study populations or the same study, only the one with the largest sample size was selected (<xref ref-type="fig" rid="pone-0100206-g001">Figure 1</xref>).</p>
<fig id="pone-0100206-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0100206.g001</object-id><label>Figure 1</label><caption>
<title>Flow diagram of study selection.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0100206.g001" position="float" xlink:type="simple"/></fig>
<p>The following data were extracted from each article: first author’s name, year of publication, country of origin, participant gender, participant age, sample size, MDS subtype, criteria for classification of MDS, karyotypes and IPSS classification. If the required data for the meta-analysis were not available in the published study, we contacted the corresponding authors for missing data.</p>
<p>A general variance-based method and a mathematical HR approximation method <xref ref-type="bibr" rid="pone.0100206-Tierney1">[19]</xref> in this meta-analysis were simultaneously used to estimate the summary HRs and their 95% CIs for the combined large sample set. Assessing heterogeneity and choosing fixed-effect or random-effect were performed as described previously <xref ref-type="bibr" rid="pone.0100206-Tong1">[20]</xref>. Sensitivity analysis was conducted by sequential omission of individual studies and evaluated influence of each study on the stability of the results. Cumulative analysis was performed by assortment of publication time. Publication bias was assessed by funnel plot and Egger’s test <xref ref-type="bibr" rid="pone.0100206-Begg1">[21]</xref>, <xref ref-type="bibr" rid="pone.0100206-Egger1">[22]</xref>. All statistical analyses were carried out in STATA 11.0 statistical software (Stata Corporation, College Station, Texas), and a <italic>P</italic>-value less than 0.05 was considered significant.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Patient Characteristics</title>
<p>The current study included 146 patients (85 men and 61 women). The median age was 55 years (range 18–85). According to the WHO criteria, 7 (4.79%) patients were classified as refractory anemia (RA), 3 (2.05%) as RA with ringed sideroblasts (RARS), 50 (34.25%) as refractory cytopenia with multilineage dysplasia (RCMD), 44 (30.14%) as RA with excess blasts type 1 (RAEB1) and 42 (28.77%) as RAEB2 <xref ref-type="bibr" rid="pone.0100206-Bennett1">[23]</xref>. Cytogenetic results were available for 141 patients. The data demonstrated a low risk in 99 patients, an intermediate risk in 26 patients and a high risk in 16 patients. IPSS risk distributions were: low risk in 7 patients (4.97%), intermediate-1 risk in 76 patients (53.90%), intermediate-2 risk in 46 patients (32.62%) and high risk in 12 patients (8.51%).</p>
</sec><sec id="s3b">
<title><italic>IDH1/2</italic> Mutations in MDS and Association with Clinical Outcomes</title>
<p><italic>IDH1/2</italic> mutations were identified in eleven (7.53%) MDS patients, six (4.11%) had mutations in <italic>IDH1</italic> and five (3.42%) had mutations in <italic>IDH2</italic> (<xref ref-type="table" rid="pone-0100206-t001">Table 1</xref>). Among MDS patients with <italic>IDH1/2</italic> mutations, two (18.18%) were classified as RAEB1, seven (63.64%) as RAEB2 and two (18.18%) as RCMD. Seven MDS patients (64.64%) with <italic>IDH</italic> mutations had a normal karyotype. Of the four patients with <italic>IDH1/2</italic> mutations and abnormal karyotypes, three (75%) carried a −7/7q-. All MDS patients with <italic>IDH1</italic> mutations carried an <italic>IDH1</italic> R132C mutation, whereas all patients with <italic>IDH2</italic> mutations carried an <italic>IDH2</italic> R140Q mutation. <italic>IDH1/2</italic> mutants carried significantly more bone marrow (BM) blasts than MDS patients with wild-type <italic>IDH1/2</italic> (<italic>P</italic> = 0.022); no significant differences were observed in age, sex, white blood cell (WBC) count, hemoglobin, platelet count, WHO subtype, cytogenetics or IPSS.</p>
<table-wrap id="pone-0100206-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0100206.t001</object-id><label>Table 1</label><caption>
<title>Characteristics of patients with MDS.</title>
</caption><alternatives><graphic id="pone-0100206-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0100206.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"><italic>IDH1</italic> mutation</td>
<td align="left" rowspan="1" colspan="1"><italic>IDH2</italic> mutation</td>
<td align="left" rowspan="1" colspan="1">Wild-type</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">(n = 6)</td>
<td align="left" rowspan="1" colspan="1">(n = 5)</td>
<td align="left" rowspan="1" colspan="1">(n = 135)</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Sex</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">0.360</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Male</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">77</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Female</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">58</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Median age, years (range)</td>
<td align="left" rowspan="1" colspan="1">69(46–74)</td>
<td align="left" rowspan="1" colspan="1">61(36–78)</td>
<td align="left" rowspan="1" colspan="1">55(18–85)</td>
<td align="left" rowspan="1" colspan="1">0.122</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Median WBC, ×10<sup>9</sup>/L (range)</td>
<td align="left" rowspan="1" colspan="1">4.1(2.2–15.6)</td>
<td align="left" rowspan="1" colspan="1">3(1.3–5.7)</td>
<td align="left" rowspan="1" colspan="1">2.8(0.4–26.4)</td>
<td align="left" rowspan="1" colspan="1">0.221</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Median hemoglobin, g/L (range)</td>
<td align="left" rowspan="1" colspan="1">94(60–102)</td>
<td align="left" rowspan="1" colspan="1">74(60–82)</td>
<td align="left" rowspan="1" colspan="1">80(39–169)</td>
<td align="left" rowspan="1" colspan="1">0.850</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Median platelets, ×10<sup>9</sup>/L (range)</td>
<td align="left" rowspan="1" colspan="1">56(20–86)</td>
<td align="left" rowspan="1" colspan="1">89(27–484)</td>
<td align="left" rowspan="1" colspan="1">70(4–542)</td>
<td align="left" rowspan="1" colspan="1">0.891</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Median blasts, %(range)</td>
<td align="left" rowspan="1" colspan="1">11.8(5–18)</td>
<td align="left" rowspan="1" colspan="1">13(2–19.5)</td>
<td align="left" rowspan="1" colspan="1">6(0.5–18.5)</td>
<td align="left" rowspan="1" colspan="1">0.022</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">WHO subtype</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">0.121</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RA</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RARS</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RCMD</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">48</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RAEB1</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">42</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RAEB2</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Karyotype classification</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">0.087</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Low risk</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">91</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Intermediate risk</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">26</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">High risk</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">13</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">IPSS</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">0.364</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Low risk</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Intermediate 1</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">72</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Intermediate 2</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">41</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">High risk</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>Abbreviations: MDS, myelodysplastic syndromes; WHO, World Health Organization; RA, refractory anemia; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, RA with excess blasts type 1; WBC, white blood cell count; IPSS, International Prognostic Scoring System.</p></fn></table-wrap-foot></table-wrap>
<p>The median survival time was 512 days (range 100–924 days) in the <italic>IDH1/2</italic> mutant group and 956 days (range, 632–1280 days) in the wild-type <italic>IDH1/2</italic> group. Survival analysis demonstrated MDS patients harboring <italic>IDH1/2</italic> mutations had significantly shorter OS compared to patients with wild-type <italic>IDH1/2</italic> (<italic>P</italic> = 0.007) (<xref ref-type="fig" rid="pone-0100206-g002">Figure 2A</xref>). Further, we found <italic>IDH1</italic> mutations negatively affected OS in MDS (<italic>P</italic> = 0.030) rather than <italic>IDH2</italic> mutations (<italic>P</italic> = 0.067) (<xref ref-type="fig" rid="pone-0100206-g002">Figure 2C, E</xref>). The presence of <italic>IDH1/2</italic> mutations did not influence the LFS (<italic>P</italic> = 0.078, 0.195 and 0.201, respectively) (<xref ref-type="fig" rid="pone-0100206-g002">Figure 2B, D, F</xref>). Interestingly, our data showed the presence of <italic>IDH1/2</italic> mutations was an adverse predictor of OS in the intermediate-1 risk group of IPSS (<italic>P</italic> = 0.039) (<xref ref-type="fig" rid="pone-0100206-g003">Figure 3A</xref>), but not in the intermediate-2 risk (<italic>P</italic> = 0.410) (<xref ref-type="fig" rid="pone-0100206-g003">Figure 3B</xref>) or high risk (<italic>P</italic> = 0.685) (<xref ref-type="fig" rid="pone-0100206-g003">Figure 3C</xref>) group. Our results also indicated that decitabine achieved a better therapeutic effect in <italic>IDH1/2</italic> mutation-positive patients compared to other treatments (including: GHA regimen, n = 3; GAA regimen, n = 2; supportive care, n = 2) (<italic>P</italic> = 0.023) (<xref ref-type="fig" rid="pone-0100206-g003">Figure 3D</xref>).</p>
<fig id="pone-0100206-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0100206.g002</object-id><label>Figure 2</label><caption>
<title>Kaplan–Meier survival curves for survival of MDS patients.</title>
<p>(A) Overall survival data for MDS patients stratified by <italic>IDH1/2</italic> mutational status. (B) Leukemia-free survival data for MDS patients stratified by <italic>IDH1/2</italic> mutational status. (C) Overall survival data for MDS patients stratified by <italic>IDH1</italic> mutational status. (D) Leukemia-free survival data for MDS patients stratified by <italic>IDH1</italic> mutational status. (E) Overall survival data for MDS patients stratified by <italic>IDH2</italic> mutational status. (F) Leukemia-free survival data for MDS patients stratified by <italic>IDH2</italic> mutational status.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0100206.g002" position="float" xlink:type="simple"/></fig><fig id="pone-0100206-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0100206.g003</object-id><label>Figure 3</label><caption>
<title>Kaplan–Meier survival curves for overall survival of MDS patients.</title>
<p>(A) Overall survival of MDS patients in the intermediate-1 risk group of IPSS. (B) Overall survival of MDS patients in the intermediate-2 risk group of IPSS. (C) Overall survival of MDS patients in the high risk group of IPSS. (D) Kaplan–Meier survival of <italic>IDH</italic> mutant patients with decitabine chemotherapy compared with other treatments.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0100206.g003" position="float" xlink:type="simple"/></fig>
<p>Multivariable analysis including <italic>IDH</italic> mutations, age, WBC count, hemoglobin, platelet count, BM blast count, cytogenetic changes and IPSS class showed HRs of <italic>IDH1/2</italic> mutations for OS and LFS were 1.83 (95%CI 0.86–3.92) (<italic>P</italic> = 0.118) and 1.18 (95%CI 0.56–2.50) (<italic>P</italic> = 0.662), respectively. In addition, HRs of mutant <italic>IDH1</italic> for OS and LFS were 1.62 (95%CI 0.55–4.81) (<italic>P</italic> = 0.383) and 1.07 (95%CI 0.37–3.09) (<italic>P</italic> = 0.903), and HRs of mutant <italic>IDH2</italic> for OS and LFS were 1.93 (95%CI 0.70–5.35) (<italic>P</italic> = 0.206) and 1.23 (95%CI 0.44–3.40) (<italic>P</italic> = 0.692), respectively.</p>
</sec><sec id="s3c">
<title>Meta-analysis Results</title>
<p>As shown in <xref ref-type="fig" rid="pone-0100206-g001">Figure 1</xref>, six studies and our data covering a total of 1782 subjects (111 with <italic>IDH1/2</italic> mutations, 1671 with wild-type <italic>IDH</italic>) were included in the meta-analysis. Two of them were from United States <xref ref-type="bibr" rid="pone.0100206-Bejar1">[3]</xref>, <xref ref-type="bibr" rid="pone.0100206-Patnaik1">[14]</xref>, one from Germany <xref ref-type="bibr" rid="pone.0100206-Thol1">[15]</xref> and three from Asia <xref ref-type="bibr" rid="pone.0100206-Lin1">[16]</xref>, <xref ref-type="bibr" rid="pone.0100206-Lin2">[17]</xref>, <xref ref-type="bibr" rid="pone.0100206-Lin3">[18]</xref> (<xref ref-type="table" rid="pone-0100206-t002">Table 2</xref>). Two of these studies found a correlation between <italic>IDH1/2</italic> mutations and adverse prognosis in MDS <xref ref-type="bibr" rid="pone.0100206-Patnaik1">[14]</xref>, <xref ref-type="bibr" rid="pone.0100206-Thol1">[15]</xref>. For all studies in this meta-analysis, MDS were diagnosed by the WHO <xref ref-type="bibr" rid="pone.0100206-Vardiman1">[13]</xref> or FAB (French-American-British) criteria <xref ref-type="bibr" rid="pone.0100206-Bennett2">[24]</xref>.</p>
<table-wrap id="pone-0100206-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0100206.t002</object-id><label>Table 2</label><caption>
<title>Main characteristics of studies involving in the meta-analysis.</title>
</caption><alternatives><graphic id="pone-0100206-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0100206.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">age</td>
<td align="left" rowspan="1" colspan="1">Sex</td>
<td align="left" rowspan="1" colspan="1">MDS subtype</td>
<td align="left" rowspan="1" colspan="1">MDS classification</td>
<td align="left" rowspan="1" colspan="1">IPSS karyotype</td>
<td align="left" rowspan="1" colspan="1">IPSS</td>
<td align="left" rowspan="1" colspan="1">Number of <italic>IDH</italic> mutation</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">study</td>
<td align="left" rowspan="1" colspan="1">Country</td>
<td align="left" rowspan="1" colspan="1">number</td>
<td align="left" rowspan="1" colspan="1">(range)</td>
<td align="left" rowspan="1" colspan="1">female</td>
<td align="left" rowspan="1" colspan="1">male</td>
<td align="left" rowspan="1" colspan="1">RA/RARS</td>
<td align="left" rowspan="1" colspan="1">RCMD</td>
<td align="left" rowspan="1" colspan="1">RAEB/RAEB-t</td>
<td align="left" rowspan="1" colspan="1">Others</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Good/Intermediate/</td>
<td align="left" rowspan="1" colspan="1">Low+Int1/Int2+</td>
<td align="left" rowspan="1" colspan="1">(<italic>IDH1/IDH2</italic>)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Poor/Unknown</td>
<td align="left" rowspan="1" colspan="1">High/Unknown</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Thol</td>
<td align="left" rowspan="1" colspan="1">Germany</td>
<td align="left" rowspan="1" colspan="1">193</td>
<td align="left" rowspan="1" colspan="1">NR(36–92)</td>
<td align="left" rowspan="1" colspan="1">119</td>
<td align="left" rowspan="1" colspan="1">74</td>
<td align="left" rowspan="1" colspan="1">38/20</td>
<td align="left" rowspan="1" colspan="1">30</td>
<td align="left" rowspan="1" colspan="1">53/0</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1">WHO</td>
<td align="left" rowspan="1" colspan="1">109/20/23/41</td>
<td align="left" rowspan="1" colspan="1">96/51/46</td>
<td align="left" rowspan="1" colspan="1">7(7/0)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">(2010) <xref ref-type="bibr" rid="pone.0100206-Thol1">[15]</xref></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bejar</td>
<td align="left" rowspan="1" colspan="1">United</td>
<td align="left" rowspan="1" colspan="1">439</td>
<td align="left" rowspan="1" colspan="1">70(NR)</td>
<td align="left" rowspan="1" colspan="1">133</td>
<td align="left" rowspan="1" colspan="1">306</td>
<td align="left" rowspan="1" colspan="1">197/47</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">160/34</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">FAB</td>
<td align="left" rowspan="1" colspan="1">310/55/67/7</td>
<td align="left" rowspan="1" colspan="1">295/133/11</td>
<td align="left" rowspan="1" colspan="1">15(6/9)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">(2011) <xref ref-type="bibr" rid="pone.0100206-Bejar1">[3]</xref></td>
<td align="left" rowspan="1" colspan="1">States</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lin</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">82</td>
<td align="left" rowspan="1" colspan="1">NR (20–85)</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">47</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">34/0</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">WHO</td>
<td align="left" rowspan="1" colspan="1">62/11/7/2</td>
<td align="left" rowspan="1" colspan="1">59/21/2</td>
<td align="left" rowspan="1" colspan="1">5(2/3)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">(2012) <xref ref-type="bibr" rid="pone.0100206-Lin1">[16]</xref></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Patnaik</td>
<td align="left" rowspan="1" colspan="1">United</td>
<td align="left" rowspan="1" colspan="1">277</td>
<td align="left" rowspan="1" colspan="1">71 (21–91)</td>
<td align="left" rowspan="1" colspan="1">78</td>
<td align="left" rowspan="1" colspan="1">199</td>
<td align="left" rowspan="1" colspan="1">0/56</td>
<td align="left" rowspan="1" colspan="1">130</td>
<td align="left" rowspan="1" colspan="1">77/0</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">WHO</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">190/87/0</td>
<td align="left" rowspan="1" colspan="1">34(8/26)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">(2012) <xref ref-type="bibr" rid="pone.0100206-Patnaik1">[14]</xref></td>
<td align="left" rowspan="1" colspan="1">States</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lin</td>
<td align="left" rowspan="1" colspan="1">China and</td>
<td align="left" rowspan="1" colspan="1">168</td>
<td align="left" rowspan="1" colspan="1">NR(60–75)</td>
<td align="left" rowspan="1" colspan="1">55</td>
<td align="left" rowspan="1" colspan="1">113</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">38</td>
<td align="left" rowspan="1" colspan="1">119/0</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">WHO</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">73/77/18</td>
<td align="left" rowspan="1" colspan="1">17(7/10)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">(2013) <xref ref-type="bibr" rid="pone.0100206-Lin2">[17]</xref></td>
<td align="left" rowspan="1" colspan="1">Japan</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lin</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">477</td>
<td align="left" rowspan="1" colspan="1">66(18–98)</td>
<td align="left" rowspan="1" colspan="1">158</td>
<td align="left" rowspan="1" colspan="1">319</td>
<td align="left" rowspan="1" colspan="1">207</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">161/56</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">FAB</td>
<td align="left" rowspan="1" colspan="1">274/87/85/1</td>
<td align="left" rowspan="1" colspan="1">256/190/1</td>
<td align="left" rowspan="1" colspan="1">22(3/19)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">(2013) <xref ref-type="bibr" rid="pone.0100206-Lin3">[18]</xref></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p>Abbreviations: MDS, myelodysplastic syndromes; WHO, World Health Organization; FAB, French American British classification; RA, refractory anemia; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, RA with excess blasts; RAEB-t, RAEB in transformation; IPSS, International Prognostic Scoring System; <italic>IDH</italic>, <italic>isocitrate dehydrogenase</italic>.</p></fn></table-wrap-foot></table-wrap>
<p>The summary HRs for OS were 1.62 (95% CI, 1.27–2.09) for <italic>IDH1/2</italic> mutations (<xref ref-type="fig" rid="pone-0100206-g004">Figure 4A</xref>), and 2.21 (95% CI, 1.45–3.38) for <italic>IDH1</italic> mutations (<xref ref-type="fig" rid="pone-0100206-g004">Figure 4C</xref>), indicating that the presence of <italic>IDH1</italic> mutations was a negative prognostic factor for OS, whereas a marginal association was discovered for <italic>IDH2</italic> mutations 1.38 (95% CI, 0.95–2.02) (<xref ref-type="fig" rid="pone-0100206-g004">Figure 4E</xref>). <xref ref-type="fig" rid="pone-0100206-g004">Figure 4B and 4D</xref> showed the results of meta analysis for LFS, the summary HRs of LFS were 2.21 (95% CI, 1.48–3.30) for <italic>IDH1/2</italic> mutations and 2.65 (95% CI, 1.53–4.59) for <italic>IDH1</italic> mutations. There was moderate heterogeneity among studies (<italic>I<sup>2</sup></italic>&lt;75%), but no publication bias was found. Since significant heterogeneity across studies was detected, we executed sensitivity analyses and the results demonstrated the robust stability of the current results.</p>
<fig id="pone-0100206-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0100206.g004</object-id><label>Figure 4</label><caption>
<title>Forest plots describing the association between <italic>IDH</italic> mutations and MDS.</title>
<p>(A) Forest plots of HR and 95% CI for <italic>IDH1/2</italic> mutations in MDS comparing with <italic>IDH</italic> wild-type by OS endpoints. (B) Forest plots of HR and 95% CI for <italic>IDH1/2</italic> mutations in MDS comparing with IDH wild-type by LFS endpoints. (C) Forest plots of HR and 95% CI for <italic>IDH</italic>1 mutations in MDS comparing with <italic>IDH</italic>1 wild-type by OS endpoints. (D) Forest plots of HR and 95% CI for <italic>IDH</italic>1 mutations in MDS comparing with <italic>IDH</italic>1 wild-type by LFS endpoints. (E) Forest plots of HR and 95% CI for <italic>IDH</italic>2 mutations in MDS comparing with <italic>IDH</italic>2 wild-type by OS endpoints. (F) Forest plots of cumulative meta-analysis of <italic>IDH</italic> mutations in association with MDS for OS by published year.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0100206.g004" position="float" xlink:type="simple"/></fig>
<p>Cumulative analysis of the relationship between <italic>IDH</italic> mutations and MDS was performed via the assortment of studies by publication time. Inclinations toward significant association were evident over time. Moreover, the 95% CI became increasingly narrow with accumulation of more data, indicating the exactness of estimates was progressively boosted by the addition of more subjects (<xref ref-type="fig" rid="pone-0100206-g004">Figure 4F</xref>).</p>
</sec></sec><sec id="s4">
<title>Discussion</title>
<p>Due to the heterogeneity that still exists in the current prognostic scoring systems of MDS, the inclusion of novel molecular markers in these systems may enhance prognostic information. Although single gene mutations are not currently included in prognostic scoring systems, they may be vital to clinical phenotypes and overall survival in MDS. Actually, a great number of single gene mutations including <italic>EZH2</italic>, <italic>SF3B1</italic>, <italic>TET2</italic>, <italic>ASXL1</italic> and <italic>TP53</italic> have been associated with the development of MDS <xref ref-type="bibr" rid="pone.0100206-Tothova1">[25]</xref>, <xref ref-type="bibr" rid="pone.0100206-Muto1">[26]</xref>. The illumination of new gene mutations may therefore improve the prevention, diagnosis, prognosis and treatment of MDS.</p>
<p>IDH is a key cytosolic enzyme in the Krebs cycle. It catalyzes the decarboxylation of isocitrate to α-KG, leading to the production of nicotinamide adenine dinucleotide phosphate (NADP) <xref ref-type="bibr" rid="pone.0100206-Krell1">[27]</xref>, <xref ref-type="bibr" rid="pone.0100206-Jin1">[28]</xref>. <italic>IDH</italic> mutations were first reported in a metastatic colon cancer in 2006 <xref ref-type="bibr" rid="pone.0100206-Sjoblom1">[29]</xref>, and then since 2010 recurring <italic>IDH</italic> mutations were successively found in MDS (3.42%∼12.27%) <xref ref-type="bibr" rid="pone.0100206-Bejar1">[3]</xref>, <xref ref-type="bibr" rid="pone.0100206-Patnaik1">[14]</xref>, <xref ref-type="bibr" rid="pone.0100206-Lin2">[17]</xref>, <xref ref-type="bibr" rid="pone.0100206-Yoshida1">[30]</xref>, <xref ref-type="bibr" rid="pone.0100206-Rocquain1">[31]</xref>, <xref ref-type="bibr" rid="pone.0100206-Kosmider1">[32]</xref>. <italic>IDH</italic> mutations impair the normal enzymes’ function, which may be associated with poor prognosis in MDS. However, prior studies have not provided a definitive link between <italic>IDH</italic> mutations and MDS. Meta-analysis is a useful statistical method for integrating results from independent studies for a specified outcome. Combining the relevant studies increases statistical power and thus makes it possible to detect effects that may be missed by individual studies. Therefore, we summarized here the current data available regarding this potential relationship and revealed several valuable points.</p>
<p>Firstly we discovered a significant relationship between <italic>IDH1/2</italic> mutations status and MDS prognosis in the Chinese population, <italic>IDH</italic> mutations predicted more adverse OS for patients with MDS (<italic>P</italic> = 0.007). Furthermore, a meta-analysis combining the current and six previously published studies on <italic>IDH1/2</italic> mutations and MDS indicated <italic>IDH1/2</italic> mutations negatively affected OS (HR, 1.62; 95% CI, 1.27–2.09) and LFS 2.21 (95% CI, 1.48–3.30). Cumulative analysis further confirmed the significant correlation, demonstrating the effect of the variant became progressively significant with each accumulation of more data over time. In addition, when we conducted subgroup analyses, our data illustrated that <italic>IDH1</italic> but not <italic>IDH2</italic> mutations negatively affected OS 2.21 (95% CI, 1.45–3.38) and LFS 2.65 (95% CI, 1.53–4.59) in patients with MDS. Secondly, the presence of <italic>IDH1/2</italic> mutations might subdivide the intermediate-1 IPSS risk group as this was associated with a shorter OS in this group (<italic>P</italic> = 0.039). Finally, we found <italic>IDH1/2</italic> mutation-positive patients with MDS who were treated with decitibine had a significantly longer OS (<italic>P</italic> = 0.023) suggesting hypomethylating agents might be an effective treatment option for these patients.</p>
<p>There are several mechanisms by which <italic>IDH1/2</italic> mutations can worsen the prognosis of patients with MDS. (1) <italic>IDH</italic> mutations occur at low frequency (3.42%–12.27%) in MDS, but <italic>IDH1/2</italic> mutations are more frequent in both de novo AML (7.5%–31%) and AML arising from MDS (7.5%) <xref ref-type="bibr" rid="pone.0100206-Thol1">[15]</xref>, <xref ref-type="bibr" rid="pone.0100206-Abbas1">[33]</xref>, <xref ref-type="bibr" rid="pone.0100206-Pardanani1">[34]</xref>, <xref ref-type="bibr" rid="pone.0100206-Tefferi1">[35]</xref>, <xref ref-type="bibr" rid="pone.0100206-Chou1">[36]</xref>, <xref ref-type="bibr" rid="pone.0100206-Chou2">[37]</xref>, indicating a role for <italic>IDH</italic> mutations in leukemic transformation of MDS. (2) At the cytogenetic level, Caramazza et al. <xref ref-type="bibr" rid="pone.0100206-Caramazza1">[38]</xref> showed a likely association between <italic>IDH1/2</italic> mutations and trisomy 8 in MDS, and our results demonstrated 75% (3/4) of <italic>IDH1/2</italic> mutants with abnormal karyotypes carried a −7/7q- karyotype. In MDS, +8 and −7/7q- karyotypes were categorized in the intermediate-risk and high-risk cytogenetic group, respectively, suggesting they were linked to poor outcome in MDS. (3) The mutant IDH proteins displayed a gain of function as they could convert the α-KG that was generated by wild-type IDH proteins into 2-hydroxyglutarate (2-HG). Recent studies <xref ref-type="bibr" rid="pone.0100206-Fathi1">[39]</xref>, <xref ref-type="bibr" rid="pone.0100206-Dinardo1">[40]</xref> reported that 2-HG was closely related to therapeutic response and relapse in AML. Since MDS and AML share many similar characteristics <xref ref-type="bibr" rid="pone.0100206-Steensma1">[41]</xref>, it is possible that 2-HG is an oncogenic factor in MDS. (4) DNA hypermethylation played a vital role in MDS pathogenesis <xref ref-type="bibr" rid="pone.0100206-Khan1">[42]</xref>. Dang et al <xref ref-type="bibr" rid="pone.0100206-Dang1">[43]</xref> reported that mutant IDH1/2 proteins produced 2-HG which competitively inhibited α-KG-dependent enzymes, such as the DNA demethylating protein TET2 (Ten-eleven translocation 2) resulting in DNA hypermethylation. Indeed, Figueroa et al. <xref ref-type="bibr" rid="pone.0100206-Figueroa1">[44]</xref> found that AML patients with <italic>IDH1/2</italic> mutations shared a similar methylation profile to those with <italic>TET2</italic> mutations, and both mutations led to a block in myeloid differentiation and leukemogenesis. This might also be a potential reason for affecting outcomes in MDS. (5) Accumulation of 2-HG might lead to DNA damage by generating reactive oxygen species (ROS) <xref ref-type="bibr" rid="pone.0100206-Ward1">[45]</xref> and inhibit EGLN (Egg-laying defective Nine) with subsequent stabilization of hypoxia-inducible factor 1α (HIF-1α) <xref ref-type="bibr" rid="pone.0100206-Zhao1">[46]</xref>. DNA damage and HIF-1α stabilization have been reported to be closely linked to MDS pathogenesis <xref ref-type="bibr" rid="pone.0100206-Tong2">[47]</xref>, <xref ref-type="bibr" rid="pone.0100206-Head1">[48]</xref>. There are thus several mechanisms by which <italic>IDH1/2</italic> mutations may contribute to MDS pathophysiology but further research is needed to elucidate their exact contributions to the disease.</p>
<p>While the findings of this study are largely consistent with previous studies on <italic>IDH1/2</italic> mutations in MDS, several limitations should be addressed. First, analyses were based on observational rather than experimental studies. Cohort studies are prone to several types of bias including selection bias and loss-to-follow-up <xref ref-type="bibr" rid="pone.0100206-Grimes1">[49]</xref>. Second, we did not uncover unpublished studies and chose to collect only published articles in English, which could bring publication bias, despite there being no significant evidence of publication bias observed in Egger’s test. Third, our study did not assess the potential effects of gene-gene interactions known to influence outcome in MDS such as <italic>TET2</italic> mutation-associated hypermethylation <xref ref-type="bibr" rid="pone.0100206-Figueroa1">[44]</xref>. Similarly, we did not account for other known genetic contributions to leukemic transformation in MDS such as <italic>ASXL1</italic> loss-of-function <xref ref-type="bibr" rid="pone.0100206-AbdelWahab1">[50]</xref>. This could lead to possible confounding in our study results. However, since <italic>IDH1/2</italic> mutations and <italic>TET2</italic> mutations were previously found to be mutually exclusive in patients with AML <xref ref-type="bibr" rid="pone.0100206-Figueroa1">[44]</xref>, it is not likely this particular interaction significantly contributed to our results.</p>
<p>In conclusion, we screened exon 4 of the <italic>IDH1/2</italic> gene in a large cohort of Chinese patients with MDS. Consistent with previous observations, we found that <italic>IDH</italic> mutations were present in some patients with MDS. <italic>IDH1</italic> mutations rather than <italic>IDH2</italic> mutations were significantly associated with shorter OS and LFS in patients with MDS. Further studies with larger sample sizes and functional assays of mutant IDH proteins are essential to decipher the role of <italic>IDH</italic> mutations in the development of MDS. Given that <italic>IDH</italic> mutations may adversely affect outcome in MDS are relatively easy to assess at diagnosis, examining <italic>IDH</italic> mutations in MDS may enhance the current prognostic scoring systems and guide patient-specific treatment in MDS. Finally, the identification of <italic>IDH</italic> mutations in the development and progression of MDS offers the promise of ameliorating the disease using targeted therapeutics against this biochemical pathway.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0100206.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0100206.s001" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p>PRISMA checklist.</p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>We sincerely thank the sample donors and clinical investigators who participated in this study. We sincerely thank Swallows Cody from NIH for the job in polishing our paper. We are deeply indebted to Pro. Bejar R and Pro. Ebert BL from Harvard Medical School and Brigham and Women’s Hospital for supplying us original data.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0100206-Corey1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Corey</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Minden</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Barber</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Kantarjian</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>JC</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Myelodysplastic syndromes: the complexity of stem-cell diseases</article-title>. <source>Nat Rev Cancer</source> <volume>7</volume>: <fpage>118</fpage>–<lpage>129</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Nimer1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nimer</surname><given-names>SD</given-names></name> (<year>2008</year>) <article-title>Myelodysplastic syndromes</article-title>. <source>Blood</source> <volume>111</volume>: <fpage>4841</fpage>–<lpage>4851</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Bejar1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bejar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Stevenson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Abdel-Wahab</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Galili</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Nilsson</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Clinical effect of point mutations in myelodysplastic syndromes</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>2496</fpage>–<lpage>2506</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Greenberg1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Greenberg</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>C</given-names></name>, <name name-style="western"><surname>LeBeau</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Fenaux</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Morel</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>International scoring system for evaluating prognosis in myelodysplastic syndromes</article-title>. <source>Blood</source> <volume>89</volume>: <fpage>2079</fpage>–<lpage>2088</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Greenberg2"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Greenberg</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Tuechler</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schanz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sanz</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Garcia-Manero</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Revised international prognostic scoring system for myelodysplastic syndromes</article-title>. <source>Blood</source> <volume>120</volume>: <fpage>2454</fpage>–<lpage>2465</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Malcovati1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Malcovati</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Germing</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Kuendgen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Della Porta</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Pascutto</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes</article-title>. <source>J Clin Oncol</source> <volume>25</volume>: <fpage>3503</fpage>–<lpage>3510</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Bejar2"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bejar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>BL</given-names></name> (<year>2011</year>) <article-title>Unraveling the molecular pathophysiology of myelodysplastic syndromes</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <fpage>504</fpage>–<lpage>515</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Shih1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shih</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>RL</given-names></name> (<year>2011</year>) <article-title>Molecular biology of myelodysplastic syndromes</article-title>. <source>Semin Oncol</source> <volume>38</volume>: <fpage>613</fpage>–<lpage>620</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-GarciaManero1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garcia-Manero</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Shan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Faderl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ravandi</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>A prognostic score for patients with lower risk myelodysplastic syndrome</article-title>. <source>Leukemia</source> <volume>22</volume>: <fpage>538</fpage>–<lpage>543</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Reitman1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reitman</surname><given-names>ZJ</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>H</given-names></name> (<year>2010</year>) <article-title>Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism</article-title>. <source>J Natl Cancer Inst</source> <volume>102</volume>: <fpage>932</fpage>–<lpage>941</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Chung1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chung</surname><given-names>YR</given-names></name>, <name name-style="western"><surname>Schatoff</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Abdel-Wahab</surname><given-names>O</given-names></name> (<year>2012</year>) <article-title>Epigenetic alterations in hematopoietic malignancies</article-title>. <source>Int J Hematol</source> <volume>96</volume>: <fpage>413</fpage>–<lpage>427</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Kaelin1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kaelin</surname><given-names>WG</given-names><suffix>Jr</suffix></name> (<year>2011</year>) <article-title>Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases</article-title>. <source>Cold Spring Harb Symp Quant Biol</source> <volume>76</volume>: <fpage>335</fpage>–<lpage>345</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Vardiman1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vardiman</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Brunning</surname><given-names>RD</given-names></name> (<year>2002</year>) <article-title>The World Health Organization (WHO) classification of the myeloid neoplasms</article-title>. <source>Blood</source> <volume>100</volume>: <fpage>2292</fpage>–<lpage>2302</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Patnaik1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patnaik</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Hanson</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Hodnefield</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Lasho</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Finke</surname><given-names>CM</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients</article-title>. <source>Leukemia</source> <volume>26</volume>: <fpage>101</fpage>–<lpage>105</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Thol1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thol</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Weissinger</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Krauter</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Damm</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis</article-title>. <source>Haematologica</source> <volume>95</volume>: <fpage>1668</fpage>–<lpage>1674</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Lin1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>W</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome</article-title>. <source>Ann Hematol</source> <volume>91</volume>: <fpage>519</fpage>–<lpage>525</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Lin2"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Nagata</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kao</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Sanada</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Okuno</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations</article-title>. <source>Haematologica</source>.</mixed-citation>
</ref>
<ref id="pone.0100206-Lin3"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Kuo</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution</article-title>. <source>Am J Hematol</source>.</mixed-citation>
</ref>
<ref id="pone.0100206-Tierney1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tierney</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Ghersi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Burdett</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sydes</surname><given-names>MR</given-names></name> (<year>2007</year>) <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source> <volume>8</volume>: <fpage>16</fpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Tong1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e67537</fpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Begg1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Egger1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname><given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Bennett1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bennett</surname><given-names>JM</given-names></name> (<year>2000</year>) <article-title>World Health Organization classification of the acute leukemias and myelodysplastic syndrome</article-title>. <source>Int J Hematol</source> <volume>72</volume>: <fpage>131</fpage>–<lpage>133</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Bennett2"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bennett</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Catovsky</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Daniel</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Flandrin</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Galton</surname><given-names>DA</given-names></name>, <etal>et al</etal>. (<year>1982</year>) <article-title>Proposals for the classification of the myelodysplastic syndromes</article-title>. <source>Br J Haematol</source> <volume>51</volume>: <fpage>189</fpage>–<lpage>199</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Tothova1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tothova</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Steensma</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>BL</given-names></name> (<year>2013</year>) <article-title>New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice</article-title>. <source>Clin Cancer Res</source> <volume>19</volume>: <fpage>1637</fpage>–<lpage>1643</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Muto1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sashida</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Oshima</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wendt</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Mochizuki-Kashio</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders</article-title>. <source>J Exp Med</source> <volume>210</volume>: <fpage>2627</fpage>–<lpage>2639</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Krell1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Krell</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Assoku</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Galloway</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mulholland</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tomlinson</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma</article-title>. <source>PLoS One</source> <volume>6</volume>: <fpage>e19868</fpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Jin1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jin</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Reitman</surname><given-names>ZJ</given-names></name>, <name name-style="western"><surname>Spasojevic</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Batinic-Haberle</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations</article-title>. <source>PLoS One</source> <volume>6</volume>: <fpage>e16812</fpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Sjoblom1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sjoblom</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Parsons</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>The consensus coding sequences of human breast and colorectal cancers</article-title>. <source>Science</source> <volume>314</volume>: <fpage>268</fpage>–<lpage>274</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Yoshida1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sanada</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kato</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kawahata</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Matsubara</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders</article-title>. <source>Leukemia</source> <volume>25</volume>: <fpage>184</fpage>–<lpage>186</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Rocquain1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rocquain</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Carbuccia</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Trouplin</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Raynaud</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Murati</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias</article-title>. <source>BMC Cancer</source> <volume>10</volume>: <fpage>401</fpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Kosmider1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kosmider</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Gelsi-Boyer</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Slama</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dreyfus</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Beyne-Rauzy</surname><given-names>O</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1094</fpage>–<lpage>1096</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Abbas1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abbas</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lugthart</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kavelaars</surname><given-names>FG</given-names></name>, <name name-style="western"><surname>Schelen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koenders</surname><given-names>JE</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value</article-title>. <source>Blood</source> <volume>116</volume>: <fpage>2122</fpage>–<lpage>2126</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Pardanani1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pardanani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lasho</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Finke</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Mai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McClure</surname><given-names>RF</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>1146</fpage>–<lpage>1151</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Tefferi1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tefferi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jimma</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sulai</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Lasho</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Finke</surname><given-names>CM</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F</article-title>. <source>Leukemia</source> <volume>26</volume>: <fpage>475</fpage>–<lpage>480</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Chou1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chou</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Ko</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia</article-title>. <source>Leukemia</source> <volume>25</volume>: <fpage>246</fpage>–<lpage>253</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Chou2"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chou</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation</article-title>. <source>Blood</source> <volume>115</volume>: <fpage>2749</fpage>–<lpage>2754</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Caramazza1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Caramazza</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lasho</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Finke</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Gangat</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dingli</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia</article-title>. <source>Leukemia</source> <volume>24</volume>: <fpage>2120</fpage>–<lpage>2122</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Fathi1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fathi</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Sadrzadeh</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Borger</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Ballen</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Amrein</surname><given-names>PC</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response</article-title>. <source>Blood</source> <volume>120</volume>: <fpage>4649</fpage>–<lpage>4652</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Dinardo1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dinardo</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Propert</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Loren</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Paietta</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia</article-title>. <source>Blood</source> <volume>121</volume>: <fpage>4917</fpage>–<lpage>4924</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Steensma1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Steensma</surname><given-names>DP</given-names></name> (<year>2006</year>) <article-title>Are myelodysplastic syndromes “cancer”? Unexpected adverse consequences of linguistic ambiguity</article-title>. <source>Leuk Res</source> <volume>30</volume>: <fpage>1227</fpage>–<lpage>1233</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Khan1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Khan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Vale</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bhagat</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes</article-title>. <source>Semin Hematol</source> <volume>50</volume>: <fpage>16</fpage>–<lpage>37</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Dang1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>White</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Gross</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Bittinger</surname><given-names>MA</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Cancer-associated IDH1 mutations produce 2-hydroxyglutarate</article-title>. <source>Nature</source> <volume>462</volume>: <fpage>739</fpage>–<lpage>744</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Figueroa1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Figueroa</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Abdel-Wahab</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation</article-title>. <source>Cancer Cell</source> <volume>18</volume>: <fpage>553</fpage>–<lpage>567</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Ward1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ward</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wise</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Abdel-Wahab</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>BD</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate</article-title>. <source>Cancer Cell</source> <volume>17</volume>: <fpage>225</fpage>–<lpage>234</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Zhao1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zha</surname><given-names>Z</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha</article-title>. <source>Science</source> <volume>324</volume>: <fpage>261</fpage>–<lpage>265</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Tong2"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Hypoxia-inducible factor-1alpha expression indicates poor prognosis in myelodysplastic syndromes</article-title>. <source>Leuk Lymphoma</source> <volume>53</volume>: <fpage>2412</fpage>–<lpage>2418</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Head1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Head</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Jacobberger</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Mosse</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jagasia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dupont</surname><given-names>W</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis</article-title>. <source>Bone Marrow Res</source> <volume>2011</volume>: <fpage>950934</fpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-Grimes1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grimes</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Schulz</surname><given-names>KF</given-names></name> (<year>2002</year>) <article-title>Cohort studies: marching towards outcomes</article-title>. <source>Lancet</source> <volume>359</volume>: <fpage>341</fpage>–<lpage>345</lpage>.</mixed-citation>
</ref>
<ref id="pone.0100206-AbdelWahab1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abdel-Wahab</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Adli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>LaFave</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hricik</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression</article-title>. <source>Cancer Cell</source> <volume>22</volume>: <fpage>180</fpage>–<lpage>193</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>